Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2007-02-20
2007-02-20
Padmanabhan, Sreenivasan (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S170000
Reexamination Certificate
active
10294512
ABSTRACT:
A method and composition for the treatment of hormone allergy is disclosed. The method relates to using progesterone dilutions, or any other steroid hormone, to treat the systemic symptoms of hormone allergy, including pain. The composition of the hormone dilutions ranges from 10−1to 10−5. The hormone dilution may be administered sublingually, or, in the alternative, an intradermal route of administration may be chosen. Hormone dilutions may be administered at daily intervals or on any other treatment schedule as required to alleviate a patient's symptoms.
REFERENCES:
patent: 4596795 (1986-06-01), Pitha
patent: 5108995 (1992-04-01), Casper
patent: 5504074 (1996-04-01), D'Amato et al.
patent: 5744463 (1998-04-01), Bair
patent: 5855920 (1999-01-01), Chein
patent: 6207646 (2001-03-01), Krieg et al.
patent: 97/45125 (1997-12-01), None
patent: 98/29122 (1998-07-01), None
Quirino et al. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clinical Experimental Allergy, vol. 26 pp. 1253-1261, 1996.
English et al. Low-dose transdermal testosterone therapy improves angina thrshold in men with chronic stable angina:A randomized, double-blind, placebo-controlled study. Circulation, (Oct. 17, 2000) 102(16) pp. 1906-1911.
O'Neil, John, “Preventing Women's Migraines”, The New York Times, Section F, p. 6, Jul. 27, 2004.
Passalacqua, et al., “Efficacy and Safety of Sublingual Immunotherapy”, Annals of Allergy, Asthma & Immunology, 93:3-12, Jul. 12, 2004.
International Search Report with Notification of Transmittal, PCT/US02/37105; 6 pages, mailed Sep. 12, 2003.
Mabry et al., “Treatment of Common Gynecologic-Endocrinologic Symptoms by Allergy Management Procedures;” Allergy Management of Common Symptoms; vol. 59, No. 5, May 1982.
Joseph B. Miller, “Relief of Premenstrual Symptoms, Dysmenorrhea, and Contraceptive Tablet Intolerance, Journal of the Medical Association of the State of Alabama, ” vol. 44, No. 2 Aug. 1974.
Dr. Farida A. Talati, “Effects of Potentised Oestrogen & Progesteron on Dysmenorrhoea”, Indian Journal of Homeopathic Medicine, p. 175, Apr.-Jun. 1990.
Supplementary European Search Report for Application No. EP 02782324, 2 pages, Feb. 24, 2005.
Rainer Rupprechta et al.'s, “Neuropsychopharmacological properties of neuroactive steroids”, Steriods: Structure, Function, and Regulation, Elsevier Science Publishers, New York, NY, vol. 64, No. 1-2, pp. 83-91, Jan. 2, 1999.
International Search Report and Written Opinion PCT/US05/13321, 12 Pgs, Nov. 15, 2005.
Kristin K. Snow et al., “Association Between Reproductive and Hormonal Factors and Age-related Maculopathy in Postmenopausal Women”, American Journal of Ophthalmology, vol. 134, No. 6, pp. 842-848, Dec. 2002.
www.nei.nih.gov; “Age Related Macular Degeneration: What You Should Know”; National Eye Institute; p. 15, Jan. 6, 2004.
John O'Neil; “Vital Signs: Patterns; Preventing Women's Migraines”; New York Times, Section F; p. 2, Jul. 27, 2004.
A. Zorgdrager et al.; “The Premenstrual Period and Exacerbations in Multiple Sclerosis”; European Neurology; vol. 48; pp. 204-206, 2002.
T. Mennini et al.; “Tianeptine, A Selective Enhancer of Serotonin Uptake in Rat Brain”; Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 336; pp. 478-482, 1987.
M. Rehavi et al.; “Upregulation of Imipramine binding and Serotonin Uptake by Estradiol in Female Rat Brain”; Brain research, vol. 410, pp. 135-139, 1987.
M.J. Owens et al.; “Role of Serotonin in the Pathophysiology of Depression: Focus on the Serotonin Transporter”; Clinical Chemistry, vol. 40, No. 2; pp. 288-295, 1994.
J.K. McQueen et al.; “Estradiol-17β Increases Serotonin Transport (SERT) mRNA Levels and the Density of SERT-binding Sites in Female Rat Brain”; Molcular Brain Research, vol. 45; pp. 13-23, 1997.
J.K. McQueen et al.; “Oestradiol-17β Increases Serotonin Transporter (SERT) Binding Sites and SERT mRNA Expression in Discrete Regions of Female Rat Brain”; The Journal of Physiology, vol. 495, p. 2, 1996.
A.D. Ogilvie et al.; “Polymorphism in Serotonin Transporter Gene Associated With Susceptibility to Major Depression”; The Lancet, vol. 347; pp. 731-733, Mar. 16, 1996.
S. Ramamoorthy et al.; “Antidepressant- and Cocaine-Sensitive Human Serotonin Transporter: Molecular Cloning, Expression, and Chromosomal Localization”; Proceedings of the National Academy of Science USA, vol. 90, pp. 2542-2546, 1993.
S. Ramamoorthy et al.; “Regulation of the Human Serotonin Transporter”; The Journal of Biological Chemistry, vol. 268, No. 29; pp. 21626-21631, 1993.
I.M. Anderson et al.; “The Efficacy of Selective Serotonin Re-Uptake Inhibitors in Derpression: A Meta-Analysis of Studies Against Tricyclic Antidepressants”; Journal of Psychopharmacology, vol. 8, No. 4; pp. 238-249, 1994.
R. Roby et al.; “Hormone Allergy”; American Journal of Reproductive Immunology; vol. 55, Issue 4; pp. 307-313, 2006.
Frankfurt et al.; “Effect of 5,7-Dihydroxy-Tryptamine, Ovariectomy and Gonadal Steroids on Serotonin Receptor Binding in Rat Brain”; Neuroendocrinology, vol. 59; pp. 245-250, 1994.
A. Weizman et al.; “Platelet Serotonin Transporter in drug-Naive Migrainous Children and Adolescents”; Biological Psychiatry, vol. 35; pp. 452-456, 1994.
S. Mendelson et al.; “Autoradiographic Analyses of the Effects of Estradiol Benzoate on [3H]paroxetine Binding in the Cerebral Cortex and Dorsal Hippocampus of Gonadectomized Male and Female Rats”; Brain Research, vol. 601; pp. 299-302, 1993.
J.L. Snyder et al.;“Autoimmune Progesterone Dermatitis and Its Manifestation as Anaphylaxis: A Case Report and Literature Review”; Annals of Allergy, Asthma & Immunology, vol. 90; pp. 469-477, 2003.
E.A. MacGregor et al.; “Prevalance of Migraine on Each Day of the Natural Menstrual Cycle”; Neurology, vol. 63; pp. 351-353, 2004.
C.L. Haggerty et al.; “The Impact of Estrogen and Progesterone on Asthma”; Annals of Allergy, Asthma, & Immunology, vol. 90; pp. 284-291, 2003.
L. Rees; “An Aetiological Study of Premenstrual Astma”; Journal of Psychosomatic Research, vol. 7; pp. 191-197, 1963.
O. Eliasson et al.; “Morbidity in Asthma in Relation to the Menstrual Cycle”; J. Allergy Cli. Immunol., vol. 77, No. 1; pp. 87-94, 1986.
C.J. Gibbs et al.; “Premenstrual Exacerbation of Asthma”; Thorax, vol. 39; pp. 833-836, 1984.
N.L. Wulfsohn et al.; “Bronchial Asthma During Menses and Pregnancy”; S. African Med. J., vol. 38; p. 173, 1964.
M.H.H. Chandler et al.; “Premenstrual Asthma; The Effect of Estrogen on Symptoms, Pulmonary Function, and β2-Receptors”; Phamacotherapy, vol. 17, No. 2; pp. 224-234, 1997.
E.M. Skobeloff et al.; “The Effects of the Menstrual Cycle on Asthma Presentations in the Emergency Department”; Arch. Intern. Med., vol. 156; pp. 1837-1840, Sep. 9, 1996.
E.J. Calabrese et al.; “Hormesis as a Biological Hypothesis”; Environmental Health Perspectives 106, Supplement 1; p. 17, 1998.
Baker & Botts L.L.P.
Kim Jennifer
Padmanabhan Sreenivasan
Roby Russell R.
LandOfFree
Methods and compositions for the treatment of pain and other... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the treatment of pain and other..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the treatment of pain and other... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3892579